Αρχική World News Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC World News Daraxonrasib Shows Antitumour Activity in Patients with Previously Treated Metastatic RAS-mutated NSCLC Από Ogkologos - 10 Σεπτεμβρίου, 2026 132 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... 12 Δεκεμβρίου, 2024 Prize winning early detection research 7 Οκτωβρίου, 2021 MGUS to Myeloma: Study Suggests Risk of Progression Can Change 13 Αυγούστου, 2019 Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... 22 Ιανουαρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma